我国生命科学及医学新型研发机构优化建设策略研究  

Optimal Constructing Measures of Novel Research and Development Institutions in Life Sciences and Medicine in China

作　　者：胡志民[1] 贾晓峰 杨俊涛[3,4,5] 祁健伟 郝莎 薛晓娟 程涛[5,6,7,8] 张伯礼 刘德培 Hu Zhimin;Jia Xiaofeng;Yang Juntao;Qi Jianwei;Hao Sha;Xue Xiaojuan;Cheng Tao;Zhang Boli;Liu Depei(School of Health Policy and Management,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;China National Health Development Research Center,Beijing 100044,China;Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences&School of Basic Medicine of the Peking Union Medical College,Beijing 100005,China;State Key Laboratory of Common Mechanism Research for Major Diseases,Beijing 100005,China;Haihe Laboratory of Cell Ecosystem,Tianjin 300462,China;Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China;National Key Laboratory of Blood Science,Tianjin 300020,China;National Clinical Research Center for Blood Diseases,Tianjin 300020,China;Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Haihe Laboratory of Modern Chinese Medicine,Tianjin 301617,China)

机构地区：[1]中国医学科学院北京协和医学院卫生健康管理政策学院,北京100730 [2]国家卫生健康委卫生发展研究中心,北京100044 [3]中国医学科学院基础医学研究所/北京协和医学院基础学院,北京100005 [4]重大疾病共性机制研究全国重点实验室,北京100005 [5]细胞生态海河实验室,天津300462 [6]中国医学科学院血液病医院(中国医学科学院血液学研究所),天津300020 [7]血液与健康全国重点实验室,天津300020 [8]国家血液系统疾病临床医学研究中心,天津300020 [9]天津中医药大学,天津301617 [10]现代中医药海河实验室,天津301617

出　　处：《中国工程科学》2023年第5期64-71,共8页Strategic Study of CAE

基　　金：中国工程院咨询项目“新时代建设一流生命科学及医学新型研发机构的机制体制研究”(2022-DFZD-05)。

摘　　要：新型研发机构是我国科技创新的重要组织形式,生命科学及医学新型研发机构面向人民生命健康,在推动生命健康及医学发展、形成多元创新主体、构建要素活跃的创新生态方面发挥了重要作用,但其建设仍处于探索阶段,亟需优化建设策略,形成稳健的可持续发展能力。本文运用政策研究、实地调查、案例研究和专家咨询等方法,梳理我国新型研发机构的政策推动与探索实践进展,分析国外类似研发机构的建设模式和运行机制,总结我国生命科学及医学新型研发机构发展面临的挑战。在此基础上,提出了我国生命科学及医学新型研发机构优化建设的策略,涵盖构建多元稳定的筹资机制、建立差异化竞争发展路径、完善优秀人才吸纳培育机制、持续创新科研组织形式、充分用好成果转化机制优势、重视提升机构学术影响力等6个方面,以更好推动生命科学及医学新型研发机构高质量发展,助力国家科技自立自强。Novel research and development(R&D)institutions are an important organizational form of scientific and technological innovation in China.Novel R&D institutions in life sciences and medicine are oriented toward people’s life and health and play an important role in promoting the development of life sciences and medicine,forming multiple innovation subjects,and building an innovation ecology with active elements.However,their construction is still in an exploration stage,and it is urgent to optimize the construction strategy and form a stable and sustainable development capability.This study used the methods of policy research,on-site research,case study,and expert consultation to summarize the progress of policy promotion and exploration practices of novel R&D institutions in China,analyzed the construction modes and operation mechanisms of similar R&D institutions abroad,and presented challenges in the development of novel R&D institutions in the field of life sciences and medicine in China.On this basis,we proposed the following strategies for optimizing the construction of novel R&D institutions in life sciences and medicine in China:(1)building up a diversified and stable funding mechanism,(2)establishing a differentiated development path,(3)improving the recruiting and cultivating mechanism of outstanding professionals,(4)continuously innovating the organizational form of scientific research,(5)exploiting the advantages of the flexible mechanism for scientific achievement transformation,and(6)enhancing the academic influence of these institutions,thereby promoting the high-quality development of these institutions and the self-reliance and strength of China in science and technology.

关 键 词：生命科学 医学 新型研发机构 建设策略 科技创新 

分 类 号：G322.2[文化科学]